Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease

NCT03634007 is registered in ClinicalTrials.gov with Lexeo Therapeutics as lead sponsor.

NCT NCT03634007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03634007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease
Lead sponsor
Lexeo Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
November 6, 2019
Completion date
November 7, 2024
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, early onset alzheimer disease